SciSparc Ltd. (SPRC) News
Follow SciSparc Ltd. (SPRC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 16 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
SPRC - SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
SPRC - SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
NEWS | Sep 23, 2026, 12:42 PM UTC
M
SciSparc unit NeuroThera pursues FDA orphan drug designation for adult Tourette
NeuroThera Labs, a SciSparc subsidiary, is pursuing FDA orphan drug designation for an adult Tourette Syndrome treatment and has engaged RK Strategies for government and public affairs support.
GEOPOLITICS | Sep 02, 2026, 12:11 PM UTC
L
SciSparc unit NeuroThera Labs reports SCI-210 autism trial enrollment momentum
SciSparc subsidiary NeuroThera Labs said it has achieved significant enrollment momentum in its SCI-210 autism clinical trial.
EQUITY | Aug 31, 2026, 08:07 PM UTC
L
SciSparc subsidiary NeuroThera reports enrollment momentum in SCI-210 trial
SciSparc says its NeuroThera Labs has achieved significant enrollment momentum in its SCI-210 autism clinical trial.
EQUITY | Aug 31, 2026, 08:03 PM UTC
L
NeuroThera Labs Engages Dr. Reuter Investor Relations
NeuroThera Labs Engages Dr. Reuter Investor Relations
EQUITY | Aug 27, 2026, 12:01 PM UTC
L
SciSparc adds Prof. Carmel Domshlak to scientific advisory board
SciSparc said it is advancing its agentic AI strategy by adding Prof. Carmel Domshlak to its scientific advisory board.
EQUITY | Aug 26, 2026, 12:37 PM UTC
L
SciSparc adds Prof. Carmel Domshlak to advisory board
SciSparc says it is advancing its agentic AI strategy after adding Prof. Carmel Domshlak to its Scientific Advisory Board.
EQUITY | Aug 26, 2026, 12:32 PM UTC
L
SciSparc unit and Clearmind publish U.S. patent application for MDMA-PEA use
SciSparc subsidiary NeuroThera Labs and Clearmind Medicine say the USPTO published a U.S. patent application covering MDMA and N-acylethanolamines, including PEA, for methods of treating PTSD, anxiety and eating disorder
REGULATION | Aug 24, 2026, 12:54 PM UTC
M
SPRC SciSparc advances mdma-N-acylethanolamines IP for PTSD
SPRC SciSparc and NeuroThera/ClearMind collaboration advances mdma-N-acylethanolamines intellectual property for the treatment of PTSD, amid rising U.S. federal support for psychedelic innovation.
REGULATION | Aug 24, 2026, 12:51 PM UTC
M
SPRC unit SciSparc advances PTSD-related MDMA-N-acylethanolamines IP
SPRC, via SciSparc and NeuroThera-Clearmind collaboration, advances intellectual property for MDMA-N-acylethanolamines aimed at treating PTSD.
EQUITY | Aug 24, 2026, 12:51 PM UTC
L
SPRC’s NeuroThera Labs completes C$5.4m financing
SciSparc’s subsidiary NeuroThera Labs completes a C$5.4 million financing, with SciSparc’s stake valued at approximately C$30 million.
EQUITY | Aug 18, 2026, 12:06 PM UTC
L
SPRC Subsidiary Gets Japanese Patent
SPRC's NeuroThera Labs granted Japanese patent for therapeutic combination
EQUITY | Aug 12, 2026, 12:25 PM UTC
M
SciSparc Subsidiary Launches Tourette Syndrome Trial
SciSparc starts phase IIb trial for Tourette treatment
EQUITY | Aug 05, 2026, 12:22 PM UTC
M
SPRC Demonstrates Quantum Workflow
SPRC's subsidiary demonstrates quantum workflow
EQUITY | Jul 31, 2026, 12:20 PM UTC
M
SPRC Advances Quantum Platform
SPRC subsidiary advances quantum platform
EQUITY | Jul 29, 2026, 12:32 PM UTC
L
SPRC Scisparc: neurothera Labs announces initiation of phase iib clinical trial at hannover Medical school in Germany for innovative treatme
SPRC Scisparc: neurothera Labs announces initiation of phase iib clinical trial at hannover Medical school in Germany for innovative treatment of tourette syndrome
EQUITY | Jul 15, 2026, 12:41 PM UTC